-
A Treatment That Came Just in Time
Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
Building COVID-19 Vaccine Confidence
Experts discussed how the cancer community can share accurate information and increase confidence in COVID-19 vaccines, both among people with cancer and the general population.
by Kevin McLaughlin
-
Immunotherapy Indications Withdrawn
In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?
by Anna Goshua
-
Immunotherapy Options for Breast Cancer
Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.
by Anna Goshua
-
What Is Tumor Mutational Burden?
The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.
by Anna Azvolinsky
-
Taking Drug Dosing Off Autopilot
Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.
by Marcus A. Banks
-
Targeted Therapy for Early-Stage Lung Cancer?
A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.
by Ashley P. Taylor
-
The Crowded Field of Checkpoint Inhibitors
Drug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
2018: This Year in Cancer News
The Cancer Today editorial staff selects some of the most interesting and impactful reporting, research and perspectives of 2018.
by Cancer Today Staff
-
Treating Cancer Based on Its Genetics, Not Its Location
Medical oncologist and sarcoma specialist George D. Demetri explains the significance of the recent approval of the oral drug Vitrakvi based on tumor genetics.
by Anna Azvolinsky
Cancer Talk
Advanced Care Planning Leads to More Comfort-based Care
Preparing for future health decisions helps ensure care is suited to your priorities.
by Karon Warren
Drop in Cancer Diagnoses Under COVID-19 Raises AlarmsResults of a recent study support concerns that pandemic disruptions resulted in finding fewer cancers.
by Kyle Bagenstose
Lung Cancer Patients Face Worse Survival After Wildfire ExposureResearchers find that lung cancer patients recovering from surgery are especially vulnerable to the health hazards of wildfires even up to a year later.
by Sandra Gordon
Choosing Between Lung Cancer Surgery and RadiationStudy suggests surgery leads to longer survival than radiation for non-small cell lung cancer, but radiation remains an important option.
by Jon Kelvey